Eisai takes US Drug Enforcement Administration to court over 'unreasonable' scheduling delay
This article was originally published in SRA
Executive Summary
Japanese drug maker Eisai has asked the US Court of Appeals for the District of Columbia to force the Drug Enforcement Administration to complete the scheduling process for the company's epilepsy drug Fycompa (perampanel)1,2.